Medscape8h
Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus, Paving Way for Pivotal Trials
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...
Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip
Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...
Fierce Biotech6d
Drug discovery pact between Charles River and Valo Health nets potential lupus asset for Flagship’s Pioneering Medicines
The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. | The drug discovery pact between Charles River Laboratories, Valo Health and ...